Natural Product (NP) Details
General Information of the NP (ID: NP2010) | |||||
---|---|---|---|---|---|
Name |
Delphinidin
|
||||
Synonyms |
Delphinidin chloride; Delphinidin; 528-53-0; Delphinidine; Delphinidol; Ephdine; Delfinidol chloride; UNII-EM6MD4AEHE; 8012-95-1; 1-Benzopyrylium, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, chloride; EM6MD4AEHE; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol chloride; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)benzopyrylium chloride; IdB 1056; CHEBI:38701; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium chloride; MFCD00016663; Paraffin, liquid, pure; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol;chloride; 3,3',4',5,5',7-Hexahydroxyflavylium chloride; Delphinidine; Delphinidol; Ephdine; IdB 1056;Delfinidol chloride; Delphinidin; CHEMBL590878; Delphinidin chloride, analytical standard; 3,3',4',5,5',7-Hexahydroxy-2-phenylbenzopyrylium chloride; CCRIS 2518; EINECS 208-437-0; C15H11O7.Cl; 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol; Delphinidinchloride; 2-(3,4,5-trihydroxyphenyl)-1-benzopyrylium-3,5,7-triol; Paraffin, liquid, technical; SCHEMBL22369; IdB-1056; DTXSID701019982; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromenium chloride; BCP15819; 6267AF; AKOS027326494; FT-0645153; FT-0665679; A11978; Q367258; Flavylium 3,3',4',5,5',7-hexahydroxy-, chloride (8CI); UNII-R911H793SU component FFNDMZIBVDSQFI-UHFFFAOYSA-N; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)chromenylium chloride; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-1lambda-chromen-1-ylium
Click to Show/Hide
|
||||
Species Origin | Aristotelia chilensis ... | Click to Show/Hide | |||
Aristotelia chilensis | |||||
Disease | Cardiovascular disease [ICD-11: BA00-BE2Z] | Phase 2 | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H11ClO7
|
||||
PubChem CID | |||||
Canonical SMILES |
C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-]
|
||||
InChI |
1S/C15H10O7.ClH/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6;/h1-5H,(H5-,16,17,18,19,20,21);1H
|
||||
InChIKey |
FFNDMZIBVDSQFI-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 8012-95-1
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage. | |||||
Arsenite | Prostate cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
Experimental
Result(s) |
Delphinidin-induced sensitization of HL-60 cells to As(III) may lead to dose reduction of As(III) in clinical application, and ultimately contribute to minimizing its side effects. | |||||
3-bromopyruvate | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Up-regulation | ROS generation | ||||
In-vitro Model | PEO1 | CVCL_2686 | BRCA2 syndrome | Homo sapiens | ||
SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Delphinidin increases the sensitivity of ovarian cancer cell lines to 3-bromopyruvate. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Vascular endothelial growth factor receptor 2 (KDR) | Molecule Info | [1] | |
KEGG Pathway | Ras signaling pathway | Click to Show/Hide | ||
2 | Rap1 signaling pathway | |||
3 | Cytokine-cytokine receptor interaction | |||
4 | Endocytosis | |||
5 | PI3K-Akt signaling pathway | |||
6 | VEGF signaling pathway | |||
7 | Focal adhesion | |||
8 | Proteoglycans in cancer | |||
NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | VEGF signaling pathway | |||
Pathway Interaction Database | HIF-2-alpha transcription factor network | Click to Show/Hide | ||
2 | Beta3 integrin cell surface interactions | |||
3 | Signaling events mediated by TCPTP | |||
4 | SHP2 signaling | |||
5 | S1P1 pathway | |||
6 | VEGF and VEGFR signaling network | |||
7 | Integrins in angiogenesis | |||
8 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
9 | Notch-mediated HES/HEY network | |||
Reactome | Neurophilin interactions with VEGF and VEGFR | Click to Show/Hide | ||
2 | VEGF binds to VEGFR leading to receptor dimerization | |||
3 | Integrin cell surface interactions | |||
4 | EPHA-mediated growth cone collapse | |||
5 | VEGFA-VEGFR2 Pathway | |||
6 | VEGFR2 mediated cell proliferation | |||
WikiPathways | Focal Adhesion | Click to Show/Hide | ||
2 | Nifedipine Activity | |||
3 | Cardiac Progenitor Differentiation | |||
4 | Signaling by VEGF | |||
5 | Angiogenesis |